Placental lactogen I Inhibitors
Placental lactogen I inhibitors belong to a specific chemical class of compounds that have been studied and designed to selectively target and inhibit the activity of placental lactogen I (PL-I). PL-I is a hormone produced by the placenta during pregnancy and is involved in regulating maternal metabolism and fetal growth. Inhibition of PL-I aims to disrupt its actions and potentially modulate the effects it exerts on maternal physiology and fetal development. The chemical structures of PL-I inhibitors can vary, including compounds that interfere with PL-I signaling pathways, production, or its interactions with receptors.
Researchers have explored various strategies to target PL-I and attenuate its effects during pregnancy. The study of PL-I inhibitors provides valuable insights into the complex regulatory mechanisms governing maternal-fetal interactions and pregnancy physiology. Continued research in this chemical class holds promise for advancing our understanding of placental biology and its potential implications in various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bromocriptine | 25614-03-3 | sc-337602A sc-337602B sc-337602 | 10 mg 100 mg 1 g | $57.00 $265.00 $567.00 | 4 | |
Bromocriptine, a dopamine agonist, can inhibit placental lactogen by activating dopamine receptors that signal through inhibitory G-proteins, leading to decreased adenylate cyclase activity and reduced cAMP levels in lactotroph cells. | ||||||
Cabergoline | 81409-90-7 | sc-203864 sc-203864A | 10 mg 50 mg | $300.00 $1055.00 | ||
Cabergoline acts similarly to Bromocriptine, as a dopamine agonist with a high affinity for dopamine D2 receptors, leading to inhibition of placental lactogen by reducing intracellular cAMP in lactotroph cells. | ||||||
Metergoline | 17692-51-2 | sc-204079 sc-204079A | 10 mg 50 mg | $80.00 $292.00 | ||
Metergoline is a serotonin and dopamine receptor antagonist that can inhibit placental lactogen by blocking dopamine receptors involved in its secretion. | ||||||
Ritanserin | 87051-43-2 | sc-203681 sc-203681A | 10 mg 50 mg | $89.00 $312.00 | 2 | |
Ritanserin, a serotonin receptor antagonist, may inhibit placental lactogen by interfering with serotonin receptors that indirectly modulate dopamine pathways involved in the secretion of placental lactogen. | ||||||
Pimozide | 2062-78-4 | sc-203662 | 100 mg | $104.00 | 3 | |
Pimozide is a dopamine receptor antagonist that can inhibit placental lactogen by blocking dopamine receptors that regulate lactotroph cells' production and secretion of the hormone. | ||||||
Domperidone | 57808-66-9 | sc-203032 sc-203032A | 50 mg 250 mg | $61.00 $287.00 | 2 | |
Domperidone, a dopamine receptor antagonist, can inhibit placental lactogen by targeting dopamine receptors that control the secretion of the hormone from lactotroph cells. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Chlorpromazine, a dopamine antagonist, can inhibit placental lactogen release by blocking dopamine receptors that are involved in the regulation of lactotroph secretion. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol, a potent dopamine D2 receptor antagonist, can inhibit placental lactogen by preventing dopamine's action in lactotroph cells, which is necessary for the hormone's secretion. | ||||||
(RS)-(±)-Sulpiride | 15676-16-1 | sc-205494 | 100 mg | $70.00 | ||
Sulpiride, a selective dopamine D2 receptor antagonist, can inhibit placental lactogen by blocking the dopaminergic control of lactotroph cells, thereby inhibiting the hormone's secretion. | ||||||
Perphenazine | 58-39-9 | sc-208161 | 100 mg | $190.00 | ||
Perphenazine, a dopamine receptor antagonist, can inhibit placental lactogen by antagonizing dopamine receptors that modulate the secretion of lactotroph derived hormones. | ||||||